Intestinal methanogen overgrowth · Workup

Intestinal Methanogen Overgrowth: A Measurement-First Workup

Intestinal methanogen overgrowth is diagnosed by breath methane, not a stool census: under the North American Consensus, methane of at least 10 ppm at any point is positive. A single fasting value of 10 ppm or more reproduced the full two-hour result at 86.4% sensitivity and 100% specificity.

Exhaled methane is one of the few gut measures that reads microbial activity rather than membership. Its criteria, its error bars and its metabolic company all shape how a primary care workup should run.

Intestinal methanogen overgrowth is one of the few gut diagnoses anchored to a measure of microbial activity rather than a species inventory. Human cells produce no hydrogen or methane, so every molecule on a breath sample reflects fermentation in the patient that day. The practical position is blunt: the census is not the activity, and exhaled hydrogen and methane say more than culture or a commercial stool report. Breath testing is not part of the Measura library; it is ordered through gastroenterology or a reference laboratory. The video Your Gut Bacteria Breathe Out Through Your Mouth presents the argument, and the protocol, performance and workflow detail follow here.

Why can’t a stool test diagnose methanogen overgrowth?

When a European expert group sent one fecal specimen to six commercial microbiome services, diversity verdicts split three ways and the same genus was reported at 14.16% and 8.41%, labeled high at one laboratory and low at another. No service disclosed its reference cohort. The deeper problem survives better laboratories: paired DNA and RNA sequencing in adult men found only 81 of 182 prevalent pathways transcribed, and methanogenesis was encoded and transcribed solely by Methanobrevibacter, rare in DNA yet among the most heavily transcribed pathways. A census averages that signal away. Consensus authors also state that current small bowel culture techniques are not satisfactory for this assessment.

I argued for the RNA readout myself, and it has a limit worth stating. Metatranscriptomic profiles vary within a person nearly as much as between people, so a single sample is durable for composition but not for activity. Breath methane is the activity measure that holds still.

What are the breath test criteria for intestinal methanogen overgrowth?

A breath result without substrate, dose, cutoff and timing is not a finding. The North American Consensus specifies lactulose 10 g or glucose 75 g for overgrowth; a hydrogen rise of at least 20 ppm from baseline by 90 minutes is positive, and methane of at least 10 ppm at any point is positive. Hydrogen, methane and carbon dioxide should be measured together, because methanogens consume four hydrogen molecules per methane molecule and can flatten the hydrogen curve. Before the consensus, thirteen case-control studies had used thirteen different methodologies.

Two older conventions are gone. After reviewing more than 15,000 lactulose tests, the consensus ruled that a double peak has no validity, and it advised against using breath testing to estimate orocecal transit. Preparation calls for four weeks off antibiotics and an 8–12 hour fast; it is not necessary to stop proton pump inhibitors, and no position was reached on probiotics.

The single fasting methane

For methane specifically, the long protocol adds little. A single fasting value of at least 10 ppm reproduced the full two-hour result at 86.4% sensitivity and 100% specificity, correlated with stool Methanobrevibacter smithii load at R = 0.65, stayed stable for 14 weeks untreated and fell within two days of antibiotics. At 5 ppm and above, the fasting value predicted excessive methane production at 96.1% sensitivity and 99.7% specificity. Clinical association is consistent: breath methane and constipation carry an odds ratio of 3.51, and methane-predominant overgrowth has five times the likelihood of constipation of hydrogen-predominant disease. Severity separation is statistically real and clinically small, 5.65 against 4.32 on the constipation scale.

How accurate is breath testing for overgrowth?

Hydrogen-based criteria are where the error bars widen. In 139 symptomatic patients who had both duodenal aspirate culture and glucose breath testing, concordance was 65.5%, and breath sensitivity against culture was 42% with specificity 84%. Pooled case-control data show 35.5% positivity in irritable bowel syndrome and 29.7% in controls. Scintigraphy classified 48% of positive glucose tests as colonic fermentation. A center that adopted the consensus protocol saw positivity move from 29.7% to 39.5%, with the added positives arriving through methane criteria. The society update states that the definition lacks precision and that treatment after a positive test remains largely empiric.

The best evidence that clearing methane changes symptoms is thin: 31 subjects in the intention-to-treat analysis, no true placebo arm, entry at methane above 3 ppm, and a post-hoc split of 15 patients. That is the evidence tier. A mediocre measurement of the right process still outperforms empiric treatment aimed at a name on a stool report.

Sequencing the workup

• Rule out overgrowth before lactose or fructose breath testing. In lactulose-positive irritable bowel syndrome, fructose positivity dropped from 62 to 3% once a week of antibiotics had been given.
• Exclude inflammation early. In adults with irritable bowel symptoms, C-reactive protein of 0.5 or less or calprotectin of 40 µg/g or less leaves an inflammatory bowel disease probability of 1% or lower. Calprotectin does not detect overgrowth.
• Consider fecal elastase-1 where maldigestion is plausible: 0.94 sensitivity and 0.69 specificity at 200 µg/g, with watery stool diluting the result.
• Report which gases were measured. No consensus body has set a hydrogen sulfide threshold, so a sulfide cutoff is the laboratory’s own.

The metabolic overlap Measura can measure

Methane positivity keeps turning up in metabolically abnormal patients. In eleven prediabetic adults with obesity, mean BMI 35.17, and positive for methane, a 10-day neomycin and rifaximin course eliminated breath methane in eight, and in those eight LDL, total cholesterol and 120-minute insulin on glucose tolerance testing improved. Energy harvest did not change, stool methanogen counts did not fall significantly, and there was no control arm. It is a hypothesis, and it supports measuring the metabolic side rather than assuming it. The society update adds a laboratory signature: elevated folate with, less commonly, vitamin B12 deficiency.

Measura [Cardiometabolic and Autonomic Health Analysis] contributes on that side, with results returned to the ordering physician:

• Laboratory panels for insulin with glucose, lipids and nutritional markers in a methane-positive patient with prediabetes or obesity.
• Bioimpedance body composition to separate lean and fat compartments where BMI is the only adiposity figure in the chart.

There is also an incentive problem to name. Commercial stool kits are built around repeat purchase and colored dashboards, while a breath measure that settles the question generates nothing further to sell. That structure explains why patients arrive with folders of reports and no gas measurement. For practice design, see selection criteria and standing orders for screening; the metabolic case in pain populations is in why metabolic health belongs in a pain practice. The patient version is the methane breath test explained, and the full study limits are in the Angry Gut companion deep dive for Chapter 25.

Frequently asked questions

References

• Rezaie, A., Buresi, M., Lembo, A., Lin, H., McCallum, R., Rao, S., Schmulson, M., Valdovinos, M., Zakko, S., & Pimentel, M. (2017). Hydrogen and methane-based breath testing in gastrointestinal disorders: The North American Consensus. The American Journal of Gastroenterology, 112(5), 775-784. https://doi.org/10.1038/ajg.2017.46
• Takakura, W., Pimentel, M., Rao, S., Villanueva-Millan, M. J., Chang, C., Morales, W., Sanchez, M., Torosyan, J., Rashid, M., Hosseini, A., Wang, J., Leite, G., Kowalewski, E., Mathur, R., & Rezaie, A. (2022). A single fasting exhaled methane level correlates with fecal methanogen load, clinical symptoms and accurately detects intestinal methanogen overgrowth. The American Journal of Gastroenterology, 117(3), 470-477. https://doi.org/10.14309/ajg.0000000000001607
• Kunkel, D., Basseri, R. J., Makhani, M. D., Chong, K., Chang, C., & Pimentel, M. (2011). Methane on breath testing is associated with constipation: A systematic review and meta-analysis. Digestive Diseases and Sciences, 56(6), 1612-8. https://doi.org/10.1007/s10620-011-1590-5
• Erdogan, A., Rao, S. S. C., Gulley, D., Jacobs, C., Lee, Y. Y., & Badger, C. (2015). Small intestinal bacterial overgrowth: Duodenal aspiration vs glucose breath test. Neurogastroenterology and Motility, 27(4), 481-9. https://doi.org/10.1111/nmo.12516
• Baker, J. R., Chey, W. D., Watts, L., Armstrong, M., Collins, K., Lee, A. A., Dupati, A., Menees, S., Saad, R. J., Harer, K., & Hasler, W. L. (2021). How the North American Consensus protocol affects the performance of glucose breath testing for bacterial overgrowth versus a traditional method. The American Journal of Gastroenterology, 116(4), 780-787. https://doi.org/10.14309/ajg.0000000000001110
• Quigley, E. M. M., Murray, J. A., & Pimentel, M. (2020). AGA Clinical Practice Update on small intestinal bacterial overgrowth: Expert review. Gastroenterology, 159(4), 1526-1532. https://doi.org/10.1053/j.gastro.2020.06.090
• Mathur, R., Chua, K. S., Mamelak, M., Morales, W., Barlow, G. M., Thomas, R., Stefanovski, D., Weitsman, S., Marsh, Z., Bergman, R. N., & Pimentel, M. (2016). Metabolic effects of eradicating breath methane using antibiotics in prediabetic subjects with obesity. Obesity (Silver Spring), 24(3), 576-82. https://doi.org/10.1002/oby.21385
• Abu-Ali, G. S., Mehta, R. S., Lloyd-Price, J., Mallick, H., Branck, T., Ivey, K. L., Drew, D. A., DuLong, C., Rimm, E., Izard, J., Chan, A. T., & Huttenhower, C. (2018). Metatranscriptome of human faecal microbial communities in a cohort of adult men. Nature Microbiology, 3(3), 356-366. https://doi.org/10.1038/s41564-017-0084-4
• Menees, S. B., Powell, C., Kurlander, J., Goel, A., & Chey, W. D. (2015). A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. The American Journal of Gastroenterology, 110(3), 444-54. https://doi.org/10.1038/ajg.2015.6
• Pimentel, M., Chang, C., Chua, K. S., Mirocha, J., DiBaise, J., Rao, S., & Amichai, M. (2014). Antibiotic treatment of constipation-predominant irritable bowel syndrome. Digestive Diseases and Sciences, 59(6), 1278-85. https://doi.org/10.1007/s10620-014-3157-8

Related reading

• Food Addiction Screening: What the Questionnaire Cannot Measure
• CIRS Diagnosis: What the Mold Evidence Supports in Screening
• Laboratory Panels

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, medical director of Measura. Last reviewed September 12, 2026.